Neuren Pharmaceuticals' shares plunged 13% following a report by US short seller Culper Research, alleging misrepresentation of the safety profile of Rett syndrome drug Daybue by licensing partner Acadia.
The report also challenged high sales estimates and suggested a sales peak in August 2023.
Neuren has not yet commented on the matter but halted trading its shares on the ASX.